comparemela.com
  1. Home
  2. Live Updates
  3. Vanesa Gregorc - Breaking News

Vanesa Gregorc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in

United statesYu wangVanesa gregorcRafael rosellChina national medical products administrationAmerican society of clinical oncologyCandiolo cancer instituteGenfleet therapeuticsClinical oncologyNational medical products administrationChief medical officerPriority review designationBreakthrough therapy designationsThailand business

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.